News Agency
Men's Weekly

Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDA

  • Written by PR Newswire

--The Phase I clinical trial will consist of 3 cohorts in healthy subjects, including single- and multiple-dose escalation studies and food effect study. The objective of Phase I trial is to find a right dose to move into the pivotal Phase II/III in COVID-19 patients

--In antiviral cellular assays with infectious SARS-CoV-2, ASC11 demonstrated...

Read more: Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDA

How a Shopify Web Developer Can Make or Break Your eCommerce Store

Launching an online store today is easier than ever — but building one that actually performs well, drives traffic, and converts visitors into loyal customers is a different story. While Shopify offers a beginner-friendly interface, if you want to build... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion